Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 407

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The role of hypoxia-inducible factors in metabolic diseases

Open access
Gonzalez, Frank J., Xie, Cen, Jiang, Changtao·2019·Nature Reviews Endocrinology

Abstract

Hypoxia-inducible factors (HIFs), a family of transcription factors activated by hypoxia, consist of three α-subunits (HIF1α, HIF2α and HIF3α) and one β-subunit (HIF1β), which serves as a heterodimerization partner of the HIFα subunits. HIFα subunits are stabilized from constitutive degradation by hypoxia largely through lowering the activity of the oxygen-dependent prolyl hydroxylases that hydroxylate HIFα, leading to their proteolysis. HIF1α and HIF2α are expressed in different tissues and regulate target genes involved in angiogenesis, cell proliferation and inflammation, and their expression is associated with different disease states. HIFs have been widely studied because of their involvement in cancer, and HIF2α-specific inhibitors are being investigated in clinical trials for the treatment of kidney cancer. Although cancer has been the major focus of research on HIF, evidence has emerged that this pathway has a major role in the control of metabolism and influences metabolic diseases such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease. Notably increased HIF1α and HIF2α signalling in adipose tissue and small intestine, respectively, promotes metabolic diseases in diet-induced disease models. Inhibition of HIF1α and HIF2α decreases the adverse diet-induced metabolic phenotypes, suggesting that they could be drug targets for the treatment of metabolic diseases.This Review focuses on the function of hypoxia-inducible factors (HIFs) in controlling metabolism and their influence in metabolic diseases (including obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease). The therapeutic potential of targeting HIFs for the treatment of metabolic diseases will also be discussed.Key pointsObesity triggers hypoxia in adipose tissue and the small intestine, which stabilizes and activates hypoxia-inducible factor (HIF)1α and HIF2α signalling, resulting in adverse metabolic effects, including insulin resistance and non-alcoholic fatty liver disease.Induction of HIF1α in adipocytes, through a suppressor of cytokine signalling 3 (SOCS3)–signal transducer and activator of transcription 3 (STAT3) axis, leads to the upregulation of inflammation and downregulation of adiponectin expression, resulting in insulin resistance.Activation of HIF2α in the small intestine increases expression of sialidase 3, resulting in an elevation of small intestinal and serum levels of ceramides that in turn potentiate obesity-associated metabolic diseases.Genetic or chemical inhibition of HIF1α and HIF2α signalling in adipose tissue and the small intestine ameliorates obesity-associated metabolic diseases, indicating that they could be targeted for treatment of metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-018-0096-z

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 28 references

Cited by

See all 407

Metadata

Authors
Gonzalez, F. J., Xie, C., & Jiang, C.
Venue
Nature Reviews Endocrinology
Published
2018-10-01
Volume
15
Issue
1
Pages
21-32
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W2892759967
Cited by
407
References
28
FWCI
2.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of hypoxia-inducible factors in metabolic diseases. https://app.cochat.ai/papers/10.1038/s41574-018-0096-z
The paper
Gonzalez, F. J., Xie, C., & Jiang, C. (2019). The role of hypoxia-inducible factors in metabolic diseases. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-018-0096-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.